TransCode Therapeutics rises as FDA authorizes clinical trial for cancer drug

Transcode Therapeutics

29/12/2022 13:45

** Shares of biotech co TransCode Therapeutics Inc  RNAZ.O 
rise 24.6% to 76 cents premarket 
    ** Co says it received written authorization from U.S. FDA
to initiate clinical trial in humans for lead drug candidate
TTX-MC138 in treating advanced solid tumors
    ** The exploratory study will test up to 12 patients,
administered with a single dose of TTX-MC138 
    ** The trial is not intended to show any therapeutic effect
but RNAZ expects it to yield critical data regarding therapeutic
dose, timing, and potential safety that could inform later-stage
clinical trials
    ** RNAZ down ~76% YTD, up to last close
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))